Ceftriaxone-AFT

国家: 新西兰

语言: 英文

来源: Medsafe (Medicines Safety Authority)

现在购买

产品特点 产品特点 (SPC)
15-11-2020

有效成分:

Ceftriaxone sodium 2.385 g (Present as 2.385g ceftriaxone Sodium*3.5H2O. Eq 2.1586g of ceft. sodium anh or 2g ceftriaxone anh)

可用日期:

AFT Pharmaceuticals Ltd

INN(国际名称):

Ceftriaxone sodium 2.1586 g (equivalent to ceftriaxone 2 g)

剂量:

2 g

药物剂型:

Powder for injection

组成:

Active: Ceftriaxone sodium 2.385 g (Present as 2.385g ceftriaxone Sodium*3.5H2O. Eq 2.1586g of ceft. sodium anh or 2g ceftriaxone anh)

每包单位数:

Vial, glass, Type 1 with rubber stopper (qilu), 1 dose unit

类:

Prescription

处方类型:

Prescription

厂商:

Qilu Antibiotics Pharmaceutical Co Ltd

疗效迹象:

Infections caused by pathogens sensitive to Ceftriaxone e.g.: · sepsis; · meningitis; · abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); · infections of the bones, joints, soft tissue, skin and of wounds; · infections in patients with impaired defence mechanisms; · renal and urinary tract infections; · respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; · genital infections, including gonorrhoea. · perioperative prophylaxis of infections.

產品總結:

Package - Contents - Shelf Life: Vial, glass, Type II with rubber stopper (Qilu Antibiotics) - 1 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, Type II with rubber stopper (qilu) - 1 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, Type 1 with rubber stopper (qilu) - 1 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, Type II with rubber stopper (Qilu Antibiotics) - 5 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, Type II with rubber stopper (qilu) - 5 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, Type 1 with rubber stopper (qilu) - 5 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, Type II with rubber stopper (Qilu Antibiotics) - 10 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, Type II with rubber stopper (qilu) - 10 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, Type 1 with rubber stopper (qilu) - 10 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light

授权日期:

2010-09-14

产品特点

                                Page 1 of 18
NEW ZEALAND DATA SHEET
1.
CEFTRIAXONE-AFT POWDER FOR INJECTION
Ceftriaxone-AFT 500 mg powder for injection.
Ceftriaxone-AFT 1 g powder for injection.
Ceftriaxone-AFT 2 g powder for injection.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Ceftriaxone-AFT 500 mg: each vial contains 500 mg ceftriaxone (as
sodium).
Ceftriaxone-AFT 1 g: each vial contains 1 g ceftriaxone (as sodium).
Ceftriaxone-AFT 2 g: each vial contains 2 g ceftriaxone (as sodium).
Excipients with known effect:
Each gram of ceftriaxone contains approximately 83 mg (3.6 mmol) of
sodium.
3.
PHARMACEUTICAL FORM
Powder for injection.
White to pale yellow powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Infections caused by pathogens sensitive to ceftriaxone e.g.:
•
sepsis;
•
meningitis;
•
abdominal infections (peritonitis, infections of the biliary and
gastrointestinal tracts);
•
infections of the bones, joints, soft tissue, skin and of wounds;
•
infections in patients with impaired defence mechanisms;
•
renal and urinary tract infections;
•
respiratory tract infections, particularly pneumonia, and ear, nose
and throat infections;
•
genital infections, including Gonorrhoea.
•
perioperative prophylaxis of infections.
4.2
DOSE AND METHOD OF ADMINISTRATION
Considerations should be given to local guidelines on appropriate use
of antibacterial agents.
Dose
_Adults and children over twelve years _
The usual dosage is 1-2 g of ceftriaxone administered once daily
(every 24 hours). In severe cases or in
infections caused by moderately sensitive organisms, the dosage may be
raised to 4 g, administered once
daily. Twice daily (12 hourly) administration may be considered where
doses greater than 2g daily are
administered.
Specific dosage schedules
Page 2 of 18
_Gonorrhoea _
For the treatment of gonorrhoea (penicillinase-producing and
non-penicillinase-producing strains), a
single IM dose of 250 mg ceftriaxone is recommended.
_Perioperative prophylaxis _
To
prevent
postoperative
infections
in
contaminated
or
potentially
conta
                                
                                阅读完整的文件